Assessment of In Vivo siRNA Delivery in Cancer Mouse Models
Assessment of In Vivo siRNA Delivery in Cancer Mouse Models
复制标题
DOI：
10.1007/978-1-4939-3378-5_15
复制
发表时间：
2016-01-01
期刊：
影响因子：
--
通讯作者：
Sood, Anil K.
中科院分区：
文献类型：
--
作者：
Hatakeyama, Hiroto;Wu, Sherry Y.;Sood, Anil K.
RNA干扰（RNAi）已迅速成为靶点发现和治疗的有力工具。小干扰RNA（siRNA）在介导序列特异性基因沉默中是高度有效的。然而，使用siRNA作为癌症治疗剂的主要障碍是它们在体内从给药部位全身递送至靶细胞。本章描述了有效地递送siRNA用于癌症治疗的方法，并详细讨论了目前评估siRNA体内药代动力学和生物分布的方法。
RNA interference (RNAi) has rapidly become a powerful tool for target discovery and therapeutics. Small interfering RNAs (siRNAs) are highly effective in mediating sequence-specific gene silencing. However, the major obstacle for using siRNAs as cancer therapeutics is their systemic delivery from the administration site to target cells in vivo. This chapter describes approaches to deliver siRNA effectively for cancer treatment and discusses in detail the current methods to assess pharmacokinetics and biodistribution of siRNAs in vivo.